The iCHIP platform measures an individual's auto-antibody repertoires in a drop of blood using microarray technology. Global patterns of antibodies are detected via proprietary sets of antigens, and analyzed to provide a highly specific diagnostic and prognostic profile of the individual.

The first iCHIP-based products to be launched are tests for diagnosis and prognosis of autoimmune diseases and transplantation rejection.

The iCHIP platform can be used for a variety of clinical functions including:

The iCHIP platform system consists of:

Early diagnosis Disease sub-classification and prognosis Personalized treatment selection Monitoring response to treatment Monitoring for disease recurrence At-risk population screening

Disposable micro-array “chip”: A small wafer that carries a collection of antigens bound to its surface in an orderly pattern, each antigen occupying a specific position on the chip. The set of antigens on the chip is specific to the clinical application. A few micro-liters of blood serum or plasma are dropped on the antigen array. Antibodies present in the tested specimen bind to the antigens recognized by them. Subtype and amount of bound autoantibody is detected and quantified using a fluorescently-labeled secondary, subtype-specific antibody.

Software: Proprietary software analyzes the measured antibody-binding signal and compares it with the system’s database to provide a probability value for the indication tested (diagnosis, prognosis etc.).

An optical reader, available from several vendors, is required for bound antibody detection and quantification.